Investor Presentaiton

51 HPV-Related Clinical Program Overview Precancerous Dysplasias (VGX-3100) • • Cervical dysplasia: Phase 2b PoC trial demonstrated a complete response in 43 out of 107 patients in regression of high-grade cervical lesions and elimination of HPV infection Vulvar dysplasia: Open-label Phase 2 trial showed 8 out of 10 women had reduction in lesion area; 2 of 10 had no virus at 6 months (interim) Anal dysplasia: Open-label Phase 2 trial showed clearance of precancerous lesions in 10 out of 20 patients, decrease in lesions for 15 of 20 (interim) Head & Neck Cancer (MEDI0457) • • Phase 1 trial for HNSCC, 2 out of 4 patients treated with MEDI0457 and 2 different PD-1 checkpoint inhibitors experienced a long-term complete response for >2 years MEDI0457 is licensed by AstraZeneca and currently in a Phase 1b/2a study in combination with durvalumab (PD-L1 checkpoint inhibitor) RRP (INO-3107) • • Pilot study for Recurrent Respiratory Papillomatosis (RRP) demonstrated a clinical benefit in 2 out of 2 patients by delaying surgery due to lack of tumor recurrence A Phase 1/2 clinical trial for treating RRP with INO-3107, which includes both HPV 6 and HPV 11 antigens, is planned INOVIO POWERING DNA MEDICINES

View entire presentation